DK3246042T3 - Lægemiddelresistent immunterapi til behandling af cancer - Google Patents

Lægemiddelresistent immunterapi til behandling af cancer Download PDF

Info

Publication number
DK3246042T3
DK3246042T3 DK17165351.2T DK17165351T DK3246042T3 DK 3246042 T3 DK3246042 T3 DK 3246042T3 DK 17165351 T DK17165351 T DK 17165351T DK 3246042 T3 DK3246042 T3 DK 3246042T3
Authority
DK
Denmark
Prior art keywords
cancer
drug
treatment
immunotherapy
resistant
Prior art date
Application number
DK17165351.2T
Other languages
English (en)
Inventor
H Trent Spencer
Anindya Dasgupta
Lawrence S Lamb
Original Assignee
Univ Emory
Childrens Heatlhcare Of Atlanta Inc
Uab Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Emory, Childrens Heatlhcare Of Atlanta Inc, Uab Res Found filed Critical Univ Emory
Application granted granted Critical
Publication of DK3246042T3 publication Critical patent/DK3246042T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Oncology (AREA)
DK17165351.2T 2009-11-02 2010-10-29 Lægemiddelresistent immunterapi til behandling af cancer DK3246042T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25713609P 2009-11-02 2009-11-02
EP10827507.4A EP2496244B8 (en) 2009-11-02 2010-10-29 Drug resistant immunotherapy for treatment of a cancer

Publications (1)

Publication Number Publication Date
DK3246042T3 true DK3246042T3 (da) 2019-10-14

Family

ID=43922989

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17165351.2T DK3246042T3 (da) 2009-11-02 2010-10-29 Lægemiddelresistent immunterapi til behandling af cancer

Country Status (6)

Country Link
US (5) US20120258532A1 (da)
EP (4) EP3552617B1 (da)
DK (1) DK3246042T3 (da)
ES (3) ES2633098T3 (da)
HK (1) HK1246677B (da)
WO (1) WO2011053750A2 (da)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2710123B1 (en) 2011-05-19 2017-07-12 Instituto de Medicina Molecular Cell line of lymphocytes comprising gamma-delta t cells, composition and production method thereof
DK2831109T3 (da) 2012-03-28 2018-02-12 Gadeta B V Kombinatorisk gamma-9-delta-2-t-celle-receptor-kædeudveksling
JP6608807B2 (ja) * 2013-05-29 2019-11-20 セレクティス Ｒｎａガイドｃａｓヌクレアーゼ系を用いることによって免疫療法のためにｔ細胞を操作するための方法
JP2019047801A (ja) * 2013-05-29 2019-03-28 セレクティスＣｅｌｌｅｃｔｉｓ Ｒｎａガイドｃａｓヌクレアーゼ系を用いることによって免疫療法のためにｔ細胞を操作するための方法
JP6976058B2 (ja) * 2013-11-22 2021-12-01 セレクティスCellectis 免疫療法のための化学療法薬耐性ｔ細胞を工学的に作製する方法
EP3105333B1 (en) 2014-02-10 2020-04-08 Emory University Expression of chimeric polypeptide with variable lymphocyte receptors on immune cells and uses for treating cancer
US10808230B2 (en) * 2015-02-24 2020-10-20 Board Of Regents, The University Of Texas System Selection methods for genetically-modified T cells
JP7105188B2 (ja) 2015-08-25 2022-07-22 ザ・ユー・エイ・ビー・リサーチ・フアンデーシヨン 幹細胞移植方法
US12005078B2 (en) * 2015-09-03 2024-06-11 The Uab Research Foundation Genetically engineered drug resistant T cells and methods of using the same
ES2987986T3 (es) 2016-06-10 2024-11-18 Gadeta B V Nuevo método para identificar cadenas de receptores de células T delta (o células T gamma) o partes de estas que intervienen en una respuesta antitumoral o antiinfecciosa
EP3500262A4 (en) * 2016-08-18 2020-03-25 The UAB Research Foundation COMPOSITIONS AND METHODS FOR CANCER IMMUNOTHERAPY
CA3044393A1 (en) * 2016-12-09 2018-06-14 The Uab Research Foundation Chimeric chlorotoxin receptors
AU2018268087B2 (en) 2017-05-18 2022-03-17 Umc Utrecht Holding B.V. Compositions and methods for cell targeting therapies
US12350312B2 (en) 2017-09-06 2025-07-08 Fred Hutchinson Cancer Center Methods for improving adoptive cell therapy
JP7638864B2 (ja) * 2018-11-08 2025-03-04 イン８バイオ、インコーポレイテッド 癌を処置するための組成物および方法
WO2023021113A1 (en) * 2021-08-18 2023-02-23 Julius-Maximilians-Universität Würzburg Hybrid tumor/cancer therapy based on targeting the resolution of or inducing transcription-replication conflicts (trcs)
WO2024173769A2 (en) 2023-02-17 2024-08-22 IN8bio, Inc. Non-signaling chimeric antigen receptor gamma delta t-cells

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69033710T2 (de) * 1989-10-24 2001-06-13 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville Sekretion vom mit Gamma-Interferon Signalpeptid gebundenen humänen Protein
WO1997032025A1 (en) * 1996-03-01 1997-09-04 Regents Of The University Of Minnesota Method for selective engraftment of drug-resistant hematopoietic stem cells
US7078034B2 (en) 1999-01-28 2006-07-18 Palmetto Health Alliance In vitro activated γ δ lymphocytes
US8066989B2 (en) * 2004-11-30 2011-11-29 Trion Pharma Gmbh Method of treating tumor growth and metastasis by using trifunctional antibodies to reduce the risk for GvHD in allogeneic antitumor cell therapy
WO2012138420A2 (en) 2011-04-08 2012-10-11 Rarecyte, Inc. Systems and methods for harvesting target particles of a suspension
HK1220614A1 (zh) 2013-03-10 2017-05-12 Baylor College Of Medicine 耐化疗免疫细胞
EP3105333B1 (en) 2014-02-10 2020-04-08 Emory University Expression of chimeric polypeptide with variable lymphocyte receptors on immune cells and uses for treating cancer
US12005078B2 (en) 2015-09-03 2024-06-11 The Uab Research Foundation Genetically engineered drug resistant T cells and methods of using the same
EP3500262A4 (en) 2016-08-18 2020-03-25 The UAB Research Foundation COMPOSITIONS AND METHODS FOR CANCER IMMUNOTHERAPY
JP7638864B2 (ja) 2018-11-08 2025-03-04 イン８バイオ、インコーポレイテッド 癌を処置するための組成物および方法

Also Published As

Publication number Publication date
EP2496244A4 (en) 2013-09-18
ES2882916T3 (es) 2021-12-03
US20250345313A1 (en) 2025-11-13
WO2011053750A3 (en) 2011-09-22
US10543233B2 (en) 2020-01-28
ES2633098T3 (es) 2017-09-19
EP2496244B8 (en) 2017-11-22
EP2496244A2 (en) 2012-09-12
US20150017137A1 (en) 2015-01-15
EP3970736A1 (en) 2022-03-23
WO2011053750A2 (en) 2011-05-05
US10322145B2 (en) 2019-06-18
US20120258532A1 (en) 2012-10-11
HK1246677B (en) 2020-06-05
EP3246042B1 (en) 2019-07-10
EP2496244B1 (en) 2017-04-12
US20190175653A1 (en) 2019-06-13
EP3552617B1 (en) 2021-07-07
EP3246042A1 (en) 2017-11-22
US20200323903A1 (en) 2020-10-15
EP3552617A1 (en) 2019-10-16
ES2743507T3 (es) 2020-02-19
US12213962B2 (en) 2025-02-04

Similar Documents

Publication Publication Date Title
DK3289876T3 (da) Forbindelser til behandling af cancer
DK3329775T3 (da) Fremgangsmåder til syntese af diarylthiohydantoin- og diarylhydantoinforbindelser
DK3520805T3 (da) Sammensætninger til behandling af myelofibrose
DK2558105T3 (da) Bardoxolonmethyl til behandling af fedme
DK3517534T3 (da) Forbindelser, der er anvendelige til behandling af cancer
DK2635282T3 (da) Sammensætninger til behandling af myelofibrose
DK3400944T3 (da) Ibat-inhibitorer til behandling af leversygdomme
EP2758080A4 (en) ANTICANCER IMMUNOTHERAPY
DK2498771T3 (da) Anvendelse af bethanechol til behandling af xerostomi
DK2897620T3 (da) Fremgangsmåde til behandling af cancer
PL3296319T3 (pl) Sposoby leczenia nowotworu jelita grubego
DK2452189T3 (da) Fremgangsmåde til identifikation af forbindelser til behandling af cancer
DK2753334T3 (da) Fap-aktiverede proteasomhæmmere til behandling af solide tumorer
DK3192520T3 (da) Terapeutiske midler til reducering af niveauerne af parathyreoideahormon
DK2504451T3 (da) Fremgangsmåder til at forudsige det kliniske forløb af cancer
DK2717941T3 (da) Behandling af cancer
DK2785349T3 (da) Kombinationsbehandling af cancer
DK3443957T3 (da) Forbindelser og sammensætninger til behandling af cancer
DK2504005T3 (da) Anvendelse af 1,3-diphenylprop-2-en-1-on-derivater til behandling af lever-sygdomme
DK3412687T3 (da) Fremgangsmåder til behandling af dlbcl
DK2704703T3 (da) Transdermale sammensætninger af ibuprofen og fremgangsmåder til anvendelse deraf
DK2598500T3 (da) Sammensætninger og fremgangsmåder til hæmning af jak-reaktionsvejen
DK3299356T3 (da) Fremgangsmåde til fremstilling af pleuromutiliner
DK2552963T3 (da) Humaniserede antistoffer mod CXCR4 til behandling af cancer
BRPI1007995A2 (pt) orto-aminoamidas para o tratamento de cãncer.